Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


21.11.2022

1 Am J Hematol
8 Ann Hematol
3 Blood
1 BMC Cancer
1 BMC Genomics
1 Bone Marrow Transplant
6 Br J Haematol
4 Cancer
1 Cancer Lett
1 Cancer Res
2 Eur J Haematol
1 Int J Hematol
2 J Clin Oncol
1 J Virol
5 Leuk Lymphoma
1 Leuk Res
6 Leukemia
2 Oncogene


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. WIECZOREK M, Labopin M, Castagna L, Brissot E, et al
    Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT.
    Am J Hematol. 2022 Nov 18. doi: 10.1002/ajh.26782.
    PubMed        


    Ann Hematol

  2. BERDEL AF, Koch R, Gerss J, Hentrich M, et al
    A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
    Ann Hematol. 2022 Nov 18. pii: 10.1007/s00277-022-05025.
    PubMed         Abstract available

  3. ZHANG YW, Su L, Tan YH, Lin H, et al
    Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Ann Hematol. 2022 Nov 15. pii: 10.1007/s00277-022-05033.
    PubMed         Abstract available

  4. DELEHAYE F, Rouger J, Brossier D, Suttorp M, et al
    Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course.
    Ann Hematol. 2022 Nov 12. pii: 10.1007/s00277-022-05024.
    PubMed         Abstract available

  5. YANG TT, Song XL, Zhao YM, Ye BD, et al
    Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients.
    Ann Hematol. 2022;101:2731-2741.
    PubMed         Abstract available

  6. DIAMANTOPOULOS PT, Kontandreopoulou CN, Stafylidis C, Vlachopoulou D, et al
    Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
    Ann Hematol. 2022;101:2711-2717.
    PubMed         Abstract available

  7. ZHANG JY, Li Y, Ma YS, Sun XJ, et al
    Clinical characteristics and prognostic factors in intracranial hemorrhage patients with hematological diseases.
    Ann Hematol. 2022;101:2617-2625.
    PubMed         Abstract available

  8. NAJIMA Y, Tachibana T, Takeda Y, Koda Y, et al
    Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study.
    Ann Hematol. 2022;101:2719-2729.
    PubMed         Abstract available

  9. TAN X, Yuan H, Li D, Sun X, et al
    Clinical and prognostic role of 2-[(18)F]FDG PET/CT and sarcopenia in treatment-naive patients with T-cell lymphoblastic lymphoma.
    Ann Hematol. 2022;101:2699-2709.
    PubMed         Abstract available


    Blood

  10. MURPHY WJ
    Giving alloHSCT a needed LIF(t).
    Blood. 2022;140:2008-2009.
    PubMed        

  11. GALLIPOLI P
    AML gets upSET when its dietary needs are unMet.
    Blood. 2022;140:2003-2004.
    PubMed        

  12. DORES GM, Linet MS, Curtis RE, Morton LM, et al
    Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia.
    Blood. 2022 Nov 15. pii: 493239. doi: 10.1182/blood.2022018051.
    PubMed        


    BMC Cancer

  13. DILLON R, Maycock S, Jackson A, Fox S, et al
    Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-gui
    BMC Cancer. 2022;22:1174.
    PubMed         Abstract available


    BMC Genomics

  14. JAKOBSEN I, Sundkvist M, Bjorn N, Green H, et al
    Early changes in gene expression profiles in AML patients during induction chemotherapy.
    BMC Genomics. 2022;23:752.
    PubMed         Abstract available


    Bone Marrow Transplant

  15. LUO C, Wu G, Huang X, Ding Y, et al
    Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis.
    Bone Marrow Transplant. 2022 Nov 10. pii: 10.1038/s41409-022-01865.
    PubMed         Abstract available


    Br J Haematol

  16. WAN Y, Zhang H, Zhang L, Cai J, et al
    Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia.
    Br J Haematol. 2022;199:587-596.
    PubMed         Abstract available

  17. WANG Y, Chen S, Chi P, Nie R, et al
    Survival prediction optimization of acute myeloid leukaemia based on T-cell function-related genes and plasma proteins.
    Br J Haematol. 2022;199:572-586.
    PubMed         Abstract available

  18. KRISTENSEN DT, Nielsen LB, Jakobsen LHK, Kristensen TC, et al
    Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study.
    Br J Haematol. 2022;199:539-548.
    PubMed         Abstract available

  19. ZHAO C, Wang S, Wang K
    Mutual exclusivity between the fusion gene CBFB::MYH11 and somatic mitochondrial mutations in acute myeloid leukaemia.
    Br J Haematol. 2022;199:e25-e29.
    PubMed        

  20. QIANG X, Chen S, Chen X
    Peritoneal infiltration by leukaemic promyelocytes in acute promyelocytic leukaemia at initial diagnosis.
    Br J Haematol. 2022;199:475.
    PubMed        

  21. KOTMAYER L, Romero-Moya D, Marin-Bejar O, Kozyra E, et al
    GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.
    Br J Haematol. 2022;199:482-495.
    PubMed         Abstract available


    Cancer

  22. WADHWA A, Chen Y, Hageman L, Hoppmann AL, et al
    Body mass index during maintenance therapy and relapse risk in children with acute lymphoblastic leukemia: A Children's Oncology Group report.
    Cancer. 2022 Nov 12. doi: 10.1002/cncr.34529.
    PubMed         Abstract available

  23. ORGEL E, Mittelman SD
    From soup to nuts: Obesity impairs chemotherapy during early and late phases of acute lymphoblastic leukemia treatment.
    Cancer. 2022 Nov 12. doi: 10.1002/cncr.34528.
    PubMed        

  24. HAN H, Yao Y, Wang H, Zhou M, et al
    Landscape and clinical impact of NOTCH mutations in newly diagnosed acute myeloid leukemia.
    Cancer. 2022 Nov 12. doi: 10.1002/cncr.34534.
    PubMed         Abstract available

  25. SHALLIS RM, Daver NG, Altman JK, Hasserjian RP, et al
    TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
    Cancer. 2022 Nov 17. doi: 10.1002/cncr.34535.
    PubMed         Abstract available


    Cancer Lett

  26. ZHOU H, Jiang Y, Huang Y, Zhong M, et al
    Therapeutic inhibition of PPARalpha-HIF1alpha-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia.
    Cancer Lett. 2022 Nov 14:215997. doi: 10.1016/j.canlet.2022.215997.
    PubMed         Abstract available


    Cancer Res

  27. ZHU LY, Yuan JB, Zhang L, He CX, et al
    Loss of MLL Induces Epigenetic Dysregulation of Rasgrf1 to Attenuate Kras-Driven Lung Tumorigenesis.
    Cancer Res. 2022;82:4153-4163.
    PubMed         Abstract available


    Eur J Haematol

  28. DANIEL A, Ghez D, Ravaiau C, Cavalieri D, et al
    Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.
    Eur J Haematol. 2022 Sep 1. doi: 10.1111/ejh.13858.
    PubMed         Abstract available

  29. KANG SH, Kim HB, Choi JS
    Upregulation of microRNA-597 in myelodysplastic syndromes induces apoptosis through FOSL2 inhibition.
    Eur J Haematol. 2022;109:680-685.
    PubMed         Abstract available


    Int J Hematol

  30. NAKAMURA Y, Itoh Y, Wakimoto N
    Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia.
    Int J Hematol. 2022 Nov 14. pii: 10.1007/s12185-022-03492.
    PubMed         Abstract available


    J Clin Oncol

  31. LAETSCH TW, Maude SL, Rives S, Hiramatsu H, et al
    Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
    J Clin Oncol. 2022 Nov 18:JCO2200642. doi: 10.1200/JCO.22.00642.
    PubMed         Abstract available

  32. HILLMEN P, Eichhorst B, Brown JR, Lamanna N, et al
    Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
    J Clin Oncol. 2022 Nov 17:JCO2200510. doi: 10.1200/JCO.22.00510.
    PubMed         Abstract available


    J Virol

  33. PETCH RJ, Gagne RB, Chiu E, Mankowski C, et al
    Feline Leukemia Virus Frequently Spills Over from Domestic Cats to North American Pumas.
    J Virol. 2022 Nov 14:e0120122. doi: 10.1128/jvi.01201.
    PubMed         Abstract available


    Leuk Lymphoma

  34. CHEN Y, Buhlinger K, Perissinotti AJ, Schepers AJ, et al
    Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase.
    Leuk Lymphoma. 2022;63:2663-2670.
    PubMed         Abstract available

  35. CHANDHOK NS, Sekeres MA
    What constitutes meaningful improvement in myelodysplastic syndromes?
    Leuk Lymphoma. 2022;63:2528-2535.
    PubMed         Abstract available

  36. SYMES E, Wang P, Lager AM, Bishop MR, et al
    TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.
    Leuk Lymphoma. 2022 Jun 18:1-4. doi: 10.1080/10428194.2022.2087070.
    PubMed        

  37. ZHANG X, Tu Y, Shen J, Feng Y, et al
    Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study.
    Leuk Lymphoma. 2022;63:2636-2644.
    PubMed         Abstract available

  38. ECTOR GICG, Geelen IGP, Dinmohamed AG, Hoogendoorn M, et al
    Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands.
    Leuk Lymphoma. 2022 Nov 11:1-9. doi: 10.1080/10428194.2022.2142055.
    PubMed         Abstract available


    Leuk Res

  39. KAYA Z, Keser E, Atalay E, Kayhan G, et al
    Two distinct syndromic children with T-acute lymphoblastic leukemia: Noonan syndrome and Sotos syndrome.
    Leuk Res. 2022;123:106981.
    PubMed        


    Leukemia

  40. CALVO X
    Should we give oligomonocytic chronic myelomonocytic leukemia a higher prominence in the next WHO Classification of Haematolymphoid Tumors?
    Leukemia. 2022 Nov 16. pii: 10.1038/s41375-022-01760.
    PubMed        

  41. CHEUNG LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, et al
    Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
    Leukemia. 2022 Nov 15. pii: 10.1038/s41375-022-01746.
    PubMed         Abstract available

  42. DUMAS PY, Raffoux E, Berard E, Bertoli S, et al
    Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
    Leukemia. 2022 Nov 14. pii: 10.1038/s41375-022-01742.
    PubMed         Abstract available

  43. SHER S, Whipp E, Walker J, Zhang P, et al
    VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
    Leukemia. 2022 Nov 14. pii: 10.1038/s41375-022-01758.
    PubMed         Abstract available

  44. MANDELL JD, Fisk JN, Cyrenne E, Xu ML, et al
    Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia.
    Leukemia. 2022 Nov 11. pii: 10.1038/s41375-022-01752.
    PubMed        

  45. JIMBO K, Hattori A, Koide S, Ito T, et al
    Genetic deletion and pharmacologic inhibition of E3 ubiquitin ligase HOIP impairs the propagation of myeloid leukemia.
    Leukemia. 2022 Nov 9. pii: 10.1038/s41375-022-01750.
    PubMed         Abstract available


    Oncogene

  46. MA D, Liu P, Hu C, Zhou Z, et al
    Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia.
    Oncogene. 2022 Nov 17. pii: 10.1038/s41388-022-02536.
    PubMed         Abstract available

  47. BURKE A, Borot F, Du X, Churchill M, et al
    A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia.
    Oncogene. 2022 Nov 10. pii: 10.1038/s41388-022-02532.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: